Latest Oncology News

Botensilimab/Balstilimab Combo Produces Deep Responses in Microsatellite Stable CRC

Botensilimab/Balstilimab Combo Produces Deep Responses in Microsatellite Stable CRC

June 29th 2022

Kristi Rosa

The combination of botensilimab and balstilimab elicited deep objective responses with evidence of durability and encouraging tolerability in heavily pretreated patients with microsatellite stable, metastatic colorectal cancer.

Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer

Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer

June 29th 2022

Jason Harris

Adding atezolizumab to neoadjuvant standard of care therapy for HER2-positive early breast cancer did not result in a better pathologic complete response compared with placebo, according to findings from the phase 3 IMpassion050 trial.

Second-Line RGX-202-01 Plus FOLFIRI/Bevacizumab Shows Early Efficacy, Safety in KRAS-Mutant CRC

Second-Line RGX-202-01 Plus FOLFIRI/Bevacizumab Shows Early Efficacy, Safety in KRAS-Mutant CRC

June 29th 2022

Kristi Rosa

A second-line combination regimen comprised of RGX-202-01, FOLFIRI and bevacizumab demonstrated an encouraging efficacy signal and a favorable toxicity profile in patients with KRAS-mutant colorectal cancer.

FDA Grants Breakthrough Therapy Designation to Talquetamab for Relapsed/Refractory Myeloma

FDA Grants Breakthrough Therapy Designation to Talquetamab for Relapsed/Refractory Myeloma

June 29th 2022

Kristi Rosa

The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.

Socazolimab Shows Early Efficacy, Safety in Recurrent or Metastatic Cervical Cancer

Socazolimab Shows Early Efficacy, Safety in Recurrent or Metastatic Cervical Cancer

June 29th 2022

Chris Ryan

Socazolimab produced encouraging response rates with an acceptable safety profile in patients with recurrent or metastatic cervical cancer, irrespective of PD-L1 status, according to findings from the dose-expansion portion of a phase 1 trial.

Latest Oncology Videos

All Oncology News

Dr. Strosberg on the Need for Additional Targeted Therapies in HCC

January 12th 2021

Jonathan R. Strosberg, MD

Jonathan R. Strosberg, MD, discusses the need to develop additional targeted therapies in hepatocellular carcinoma.

Dr. Chalabi on the Importance of Testing for MSI and dMMR in CRC

January 12th 2021

Myriam Chalabi, MD

Myriam Chalabi, MD, highlights the importance of testing for microsatellite instability and mismatch repair deficiency in colorectal cancer.

Dr. Braunstein on the Role of Daratumumab in Multiple Myeloma

January 12th 2021

Marc J. Braunstein, MD, PhD

Marc J. Braunstein, MD, PhD, discusses the role of daratumumab in multiple myeloma.

Dr. Shah on the Rationale for Tandem Receptor CAR T-Cell Therapy in Non-Hodgkin Lymphoma

January 11th 2021

Nirav N. Shah, MD

Nirav N. Shah, MD, discusses the rationale to evaluate tandem receptor CAR T-cell therapy in non-Hodgkin lymphoma.

Dr. Frigault on Toxicity Differences Among CAR T-Cell Products in Leukemias, Lymphomas

January 11th 2021

Matthew J. Frigault, MD

Matthew Frigault, MD, discusses differences in the toxicities experienced with CAR T-cell products used in the treatment of patients with leukemias and lymphomas.

Dr. Gomella on the Role of Genetic Testing in Prostate Cancer

January 11th 2021

Leonard G. Gomella, MD

Leonard G. Gomella, MD, discusses the role of genetic testing in prostate cancer.

Dr. Puechl on Choosing Between PARP Inhibitors in Ovarian Cancer

January 11th 2021

Allison M. Puechl, MD

Allison M. Puechl, MD, discusses choosing between PARP inhibitors in ovarian cancer.

Dr. Sznol on the Multidisciplinary Management of Immunotherapy-Associated Toxicities in Melanoma

January 11th 2021

Mario Sznol, MD

Mario Sznol, MD, Yale Cancer Center, discusses the multidisciplinary management of toxicities associated with immunotherapy in patients with melanoma.

Powles and Rini Put ctDNA Into Perspective in Urothelial Cancer

January 11th 2021

OncLive Staff

In our exclusive interview, Dr. Powles and Dr. Rini provide insight into an analysis of the phase 3 IMvigor010 study and its implications for circulating tumor DNA as a biomarker in urothelial cancer and beyond.

FDA Grants Fast Track Status to Cavrotolimod for Merkel Cell Carcinoma, CSCC

January 11th 2021

Kristi Rosa

January 11, 2021 - The FDA has granted fast track designations to cavrotolimod for use in combination with a PD-1 therapy in patients with locally advanced or metastatic Merkel cell carcinoma that is refractory to previous PD-1 blockade and for use in combination with a PD-1/PD-L1 agent in those with advanced or metastatic cutaneous squamous cell carcinoma that is refractory to previous PD-1/PD-L1 blockade.

Fleshing Out HER2-Directed Therapies in GI Malignancies

January 11th 2021

Jessica Hergert

The field of HER2-positive gastrointestinal malignancies witnessed a surge of data in 2020 regarding investigational agents, such as the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki, that could play a pivotal role in transforming treatment selection in the coming years.

FDA Grants Orphan Drug Designation to PVSRIPO for Advanced Melanoma

January 11th 2021

Kristi Rosa

January 11, 2021 — The FDA has granted an orphan drug designation to the novel intratumoral immunotherapy agent PVSRIPO for the treatment of patients with advanced melanoma, specifically those with stage IIIB-IV disease.

Questions Remain Regarding PARP Inhibition in Recurrent Platinum-Sensitive Ovarian Cancer

January 11th 2021

Brittany Cote

Joshua G. Cohen, MD, FACOG, FACS, discusses the efficacy of PARP inhibitors in ovarian cancer, remaining questions regarding repeat inhibition and treatment duration, and the potential for combinations.

Addition of Darolutamide May Augment Standard Treatment for Localized, Very High-Risk Prostate Cancer

January 11th 2021

Erica DiNapoli

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the benefit achieved with standard-of-care radiation therapy plus androgen deprivation therapy with a luteinising hormone-releasing hormone analogue.

Larotrectinib Elicits Durable Responses, Extends Survival in TRK+ Sarcomas

January 11th 2021

Kristi Rosa

January 11, 2021 - Larotrectinib was found to induce a high response rate with long durability and improve survival in patients with TRK-positive sarcomas, according to results from an analysis of 3 clinical trials.

See All News